Show simple item record

dc.contributor.authorNess, Nora
dc.contributor.authorAndersen, Sigve
dc.contributor.authorKhanehkenari, Mehrdad Rakaee
dc.contributor.authorNordbakken, Cecilie V.
dc.contributor.authorValkov, Andre
dc.contributor.authorPaulsen, Erna-Elise
dc.contributor.authorNordby, Yngve
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorDønnem, Tom
dc.contributor.authorBusund, Lill-Tove
dc.contributor.authorRichardsen, Elin
dc.date.accessioned2017-08-30T06:18:57Z
dc.date.available2017-08-30T06:18:57Z
dc.date.issued2017-03-01
dc.description.abstractProgrammed cell death protein 1 (PD-1) and its ligand Programmed death ligand 1 (PD-L1) have gained massive attention in cancer research due to recent availability and their targeted antitumor effects. Their role in prostate cancer is still undetermined. We constructed tissue microarrays from prostatectomy specimens from 535 prostate cancer patients. Following validation of antibodies, immunohistochemistry was used to evaluate the expression of PD-1 in lymphocytes and PD-L1 in epithelial and stromal cells of primary tumors. PD-L1 expression was commonly seen in tumor epithelial cells (92% of cases). Univariate survival analysis revealed a positive association between a high density of PD-1+ lymphocytes and worse clinical failure-free survival, limited to a trend (p = 0.084). In subgroups known to indicate unfavorable prostate cancer prognosis (Gleason grade 9, age < 65, preoperative PSA > 10, pT3) patients with high density of PD-1+ lymphocytes had a significantly higher risk of clinical failure (p = < 0.001, p = 0.025, p = 0.039 and p = 0.011, respectively). In the multivariate analysis, high density of PD-1+ lymphocytes was a significant negative independent prognostic factor for clinical failure-free survival (HR = 2.48, CI 95% 1.12–5.48, p = 0.025).en_US
dc.identifier.citationNess N, Andersen S, Khanehkenari MR, et al. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget. 2017;8(16):26789-26801. doi:10.18632/oncotarget.15817.en_US
dc.identifier.cristinIDFRIDAID 1472559
dc.identifier.doi10.18632/oncotarget.15817
dc.identifier.issn1949-2553
dc.identifier.urihttps://hdl.handle.net/10037/11397
dc.language.isoengen_US
dc.publisherImpact Journalsen_US
dc.relation.ispartofNess, N. (2021). Immunological biomarkers in prostate cancer - A retrospective cohort study utilizing immunohistochemistry on tissue microarrays for evaluation of immune biomarker expression and experimental in vitro assays. (Doctoral thesis). <a href=https://hdl.handle.net/10037/21237>https://hdl.handle.net/10037/21237</a>.
dc.relation.journalOncoTarget
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk mikrobiologi: 715en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Medical microbiology: 715en_US
dc.titleThe prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohorten_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record